Therapeutic targeting of the IL-13 pathway in skin inflammation

Current Understanding of Pathophysiological Mechanisms of Atopic Dermatitis: Interactions among Skin Barrier Dysfunction, Immune Abnormalities and Pruritus

(2020) Masanori Fujii   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Efficacy of biologics in atopic dermatitis

(2020) Jianni Wu et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis

(2020) Emma Guttman-Yassky et al.   JAMA Dermatology

Implications of IL-13Rα2 in atopic skin inflammation

(2020) Masutaka Furue et al.   ALLERGOLOGY INTERNATIONAL

Periostin Activation of Integrin Receptors on Sensory Neurons Induces Allergic Itch

(2020) Santosh K. Mishra et al.   Cell Reports

Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis

(2020) Aaron M. Drucker et al.   JAMA Dermatology

Microbiome Composition and Its Impact on the Development of Allergic Diseases

(2020) Diego G. Peroni et al.   Frontiers in Immunology

Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis

(2020) Shelley K. Uppal et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial

(2020) Amy S. Paller et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

(2020) Eric L Simpson et al.   LANCET

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis

(2020) Jonathan I. Silverberg et al.   JAMA Dermatology

Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial

(2020) J.I. Silverberg et al.   BRITISH JOURNAL OF DERMATOLOGY

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)

(2020) A. Wollenberg et al.   BRITISH JOURNAL OF DERMATOLOGY

Atopic dermatitis endotypes and implications for targeted therapeutics

(2019) Tali Czarnowicki et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Atopic dermatitis is an IL-13 dominant disease with greater molecular heterogeneity compared to psoriasis

(2019) Lam C. Tsoi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

(2019) Sarah Faiz et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Current and emerging biologic and small molecule therapies for atopic dermatitis

(2019) Randall Li et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Understanding the Immune Landscape in Atopic Dermatitis: The Era of Biologics and Emerging Therapeutic Approaches

(2019) Matthew Moyle et al.   EXPERIMENTAL DERMATOLOGY

Pathophysiology of atopic dermatitis: Clinical implications

(2019) Jihyun Kim et al.   ALLERGY AND ASTHMA PROCEEDINGS

Conjunctivitis in dupilumab clinical trials

(2019) B. Akinlade et al.   BRITISH JOURNAL OF DERMATOLOGY

What’s New in Atopic Dermatitis

(2019) Yael Renert-Yuval et al.   DERMATOLOGIC CLINICS

Dupilumab-asssoziierte Abheilung einer Alopecia areata bei Atopischem Ekzem

(2019) Nora Aszodi et al.   DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT

Case of alopecia areata during dupilumab treatment for atopic dermatitis

(2019) Naoko Kanda et al.   JOURNAL OF DERMATOLOGY

Periostin is induced by IL-4/IL-13 in dermal fibroblasts and promotes RhoA/ROCK pathway-mediated TGF-β1 secretion in abnormal scar formation

(2019) Daisuke Maeda et al.   Journal of Plastic Surgery and Hand Surgery

Interleukin‐13: Targeting an underestimated cytokine in atopic dermatitis

(2019) Thomas Bieber   ALLERGY

Transcriptional Control and Transcriptomic Analysis of Lipid Metabolism in Skin barrier formation and Atopic Dermatitis (AD)

(2019) Nilika Bhattacharya et al.   Expert Review of Proteomics

Scratching Counteracts IL-13 Signaling by Upregulating the Decoy Receptor IL-13Rα2 in Keratinocytes

(2019) Dugarmaa Ulzii et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study

(2019) Mette Deleuran et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets

(2019) Julie K. Nguyen et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Chitinase 3‐like 1 drives allergic skin inflammation via Th2 immunity and M2 macrophage activation

(2019) Eun Ji Kwak et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Mechanisms of Dupilumab

(2019) Hani Harb et al.   CLINICAL AND EXPERIMENTAL ALLERGY

The emerging utility of the cutaneous microbiome in the treatment of acne and atopic dermatitis

(2019) Taylor E. Woo et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase II a open‐label trial and subsequent phase III open‐label extension

(2019) M.J. Cork et al.   BRITISH JOURNAL OF DERMATOLOGY

The IL ‐13– OVOL 1– FLG axis in atopic dermatitis

(2019) Kazuhisa Furue et al.   IMMUNOLOGY

Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial

(2019) Emma Guttman-Yassky et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Interleukin-33 in atopic dermatitis

(2019) Yasutomo Imai   JOURNAL OF DERMATOLOGICAL SCIENCE

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis

(2019) Eric L. Simpson et al.   JAMA Dermatology

Interleukin-4 and interleukin-13 as possible therapeutic targets in systemic sclerosis

(2019) Giulia Gasparini et al.   CYTOKINE

The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma

(2019) Giancarlo Marone et al.   Frontiers in Pharmacology

The IL-13/periostin/IL-24 pathway causes epidermal barrier dysfunction in allergic skin inflammation

(2018) Yasutaka Mitamura et al.   ALLERGY

Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis

(2018) James E. Frampton et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Therapeutic Targeting of the Interleukin-4/Interleukin-13 Signaling Pathway: In Allergy and Beyond

(2018) Danielle Karo-Atar et al.   BIODRUGS

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t

(2018) M. de Bruin-Weller et al.   BRITISH JOURNAL OF DERMATOLOGY

Recent evolution of the human skin barrier

(2018) Erin A. Brettmann et al.   EXPERIMENTAL DERMATOLOGY

Tissue-Restricted Adaptive Type 2 Immunity Is Orchestrated by Expression of the Costimulatory Molecule OX40L on Group 2 Innate Lymphoid Cells

(2018) Timotheus Y.F. Halim et al.   IMMUNITY

Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study

(2018) Kenji Kabashima et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

New mechanism underlying IL-31–induced atopic dermatitis

(2018) Jianghui Meng et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Serum from Asian patients with atopic dermatitis is characterized by T H 2/T H 22 activation, which is highly correlated with nonlesional skin measures

(2018) Huei-Chi Wen et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb

(2018) Andreas Wollenberg et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)

(2018) Eric L. Simpson et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II

(2018) A. Wollenberg et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Staphylococcus aureus and Atopic Dermatitis: A Complex and Evolving Relationship

(2018) Joan A. Geoghegan et al.   TRENDS IN MICROBIOLOGY

Significance of Skin Barrier Dysfunction in Atopic Dermatitis

(2018) Byung Eui Kim et al.   Allergy Asthma & Immunology Research

Microbiome in the Gut-Skin Axis in Atopic Dermatitis

(2018) So-Yeon Lee et al.   Allergy Asthma & Immunology Research

Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes

(2018) Ilkka S. Junttila   Frontiers in Immunology

Atopic dermatitis in African American patients is TH2/TH22-skewed with TH1/TH17 attenuation

(2018) Riana D. Sanyal et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP/IL13 bispecific antibodies

(2018) Sathyadevi Venkataramani et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Alopecia Areata in Severe Atopic Dermatitis Treated With Dupilumab

(2018) B Barroso-García et al.   JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY

Tezepelumab, an anti-TSLP monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial

(2018) Eric L. Simpson et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Hair Regrowth in a Patient With Long-standing Alopecia Totalis and Atopic Dermatitis Treated With Dupilumab

(2018) Lauren R. Penzi et al.   JAMA Dermatology

Leveraging Multilayered “Omics” Data for Atopic Dermatitis: A Road Map to Precision Medicine

(2018) Debajyoti Ghosh et al.   Frontiers in Immunology

Commonality of the IL-4/IL-13 pathway in atopic diseases

(2017) Namita A. Gandhi et al.   Expert Review of Clinical Immunology

Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go?

(2017) Thomas Bieber et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Increased frequencies of basophils, type 2 innate lymphoid cells and Th2 cells in skin of patients with atopic dermatitis but not psoriasis

(2017) Shunya Mashiko et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2

(2017) B. Popovic et al.   JOURNAL OF MOLECULAR BIOLOGY

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

(2017) Andrew Blauvelt et al.   LANCET

Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis

(2017) Thomas Ruzicka et al.   NEW ENGLAND JOURNAL OF MEDICINE

Aryl hydrocarbon receptor activation restores filaggrin expression via OVOL1 in atopic dermatitis

(2017) Gaku Tsuji et al.   Cell Death & Disease

Stratum Corneum Tape Stripping: Monitoring of Inflammatory Mediators in Atopic Dermatitis Patients Using Topical Therapy

(2016) Sjors A. Koppes et al.   INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY

Early-onset pediatric atopic dermatitis is T H 2 but also T H 17 polarized in skin

(2016) Hitokazu Esaki et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Influence of Th2 Cytokines on the Cornified Envelope, Tight Junction Proteins, and β-Defensins in Filaggrin-Deficient Skin Equivalents

(2016) Stefan Hönzke et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Atopic dermatitis

(2016) Stephan Weidinger et al.   LANCET

Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial

(2016) Diamant Thaçi et al.   LANCET

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

(2016) Eric L. Simpson et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-13Rα2 uses TMEM219 in chitinase 3-like-1-induced signalling and effector responses

(2016) Chang-Min Lee et al.   Nature Communications

Periostin and Interleukin-13 Are Independently Related to Chronic Spontaneous Urticaria

(2016) Youin Bae et al.   Allergy Asthma & Immunology Research

Modulation of pulmonary fibrosis by IL-13Rα2

(2015) Robert V. Lumsden et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-co

(2015) O. Nemoto et al.   BRITISH JOURNAL OF DERMATOLOGY

Commentary: IL-4 and IL-13 receptors and signaling

(2015) Sarah M. McCormick et al.   CYTOKINE

The differential expression of IL-4 and IL-13 and its impact on type-2 immunity

(2015) Katherine Bao et al.   CYTOKINE

IL-33 impacts on the skin barrier by downregulating the expression of filaggrin

(2015) Jenny Seltmann et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization

(2015) Shinji Noda et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)+ TH2/TH1 cell imbalance, whereas adults acquire CLA+ TH22/TC22 cell subsets

(2015) Tali Czarnowicki et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin

(2015) K. Szegedi et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Targeting key proximal drivers of type 2 inflammation in disease

(2015) Namita A. Gandhi et al.   NATURE REVIEWS DRUG DISCOVERY

Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics

(2015) Yasaman Mansouri et al.   Journal of Clinical Medicine

IL-4 and IL-13 receptors: Roles in immunity and powerful vaccine adjuvants

(2014) Charani Ranasinghe et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis

(2014) Lisa A. Beck et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-33 Promotes the Induction and Maintenance of Th2 Immune Responses by Enhancing the Function of OX40 Ligand

(2014) Naoko Murakami-Satsutani et al.   ALLERGOLOGY INTERNATIONAL

Formation and functions of the corneocyte lipid envelope (CLE)

(2013) Peter M. Elias et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

T-helper and regulatory T-cell cytokines in the peripheral blood of patients with active alopecia areata

(2013) M.K. Tembhre et al.   BRITISH JOURNAL OF DERMATOLOGY

Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis

(2013) Mayte Suárez-Fariñas et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

The role of IL-22 and Th22 cells in human skin diseases

(2013) Hideki Fujita   JOURNAL OF DERMATOLOGICAL SCIENCE

Structural Basis of Signaling Blockade by Anti-IL-13 Antibody Lebrikizumab

(2013) Mark Ultsch et al.   JOURNAL OF MOLECULAR BIOLOGY

Cytokine mediated tissue fibrosis

(2012) Lee A. Borthwick et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis

(2012) H. H. Kong et al.   GENOME RESEARCH

Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis

(2012) Julia K. Gittler et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Follow-Up Study of the First Genome-Wide Association Scan in Alopecia Areata: IL13 and KIAA0350 as Susceptibility Loci Supported with Genome-Wide Significance

(2012) Dagny Jagielska et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Atopic dermatitis: a disease of altered skin barrier and immune dysregulation

(2011) Mark Boguniewicz et al.   IMMUNOLOGICAL REVIEWS

Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities

(2011) Mayte Suárez-Fariñas et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Low diversity of the gut microbiota in infants with atopic eczema

(2011) Thomas R. Abrahamsson et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

IL-13 Induces Skin Fibrosis in Atopic Dermatitis by Thymic Stromal Lymphopoietin

(2011) M.-H. Oh et al.   JOURNAL OF IMMUNOLOGY

Cytokine modulation of atopic dermatitis filaggrin skin expression

(2009) Michael D. Howell et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6

(2008) Byung Eui Kim et al.   CLINICAL IMMUNOLOGY

Untangling the Complex Web of IL-4- and IL-13-Mediated Signaling Pathways

(2008) M. Wills-Karp et al.   Science Signaling

Reduced diversity in the early fecal microbiota of infants with atopic eczema

(2007) Mei Wang et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY